Kiri Granger
Executive Director, Co-Founder & Chief Scientific Officer Monument Therapeutics
With 10 years of industry experience, Kiri is a highly regarded expert in the CNS field, particularly in schizophrenia. During her role as Director of Neuroscience at Cambridge Cognition, she was lead scientist on over 100 clinical trial programs and gained recognition for her innovative strategies that successfully demonstrated the efficacy of compounds following negative trial results.
During her PhD at the University of Nottingham, Kiri developed the biomarker that is now integral to Monument’s schizophrenia program, helping to establish the company’s precision medicine approach. She is an inventor on multiple patents and serves as Assistant Professor in the Department of Psychology at the University of Nottingham, reflecting her commitment to advancing research in neuroscience.
Seminars
- Neuroscience drug development has historically suffered a low success rate, in part due to a lack of diagnostic specificity
- We are entering a new era of precision medicine in psychiatry and neurology, enabled by novel digital biomarkers
- Monument Tx is a clinical-stage biotech company developing stratified therapeutics for schizophrenia and neuroinflammation, exemplifying this approach
